Cortexyme Inc
NASDAQ:CRTX
Intrinsic Value
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. [ Read More ]
The intrinsic value of one CRTX stock under the Base Case scenario is 2.59 USD. Compared to the current market price of 1.33 USD, Cortexyme Inc is Undervalued by 49%.
Valuation Backtest
Cortexyme Inc
Run backtest to discover the historical profit from buying and selling CRTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cortexyme Inc
Current Assets | 93.7m |
Cash & Short-Term Investments | 90.2m |
Other Current Assets | 3.6m |
Non-Current Assets | 10.2m |
Long-Term Investments | 3.6m |
PP&E | 684k |
Intangibles | 5.9m |
Current Liabilities | 3.1m |
Accounts Payable | 570k |
Accrued Liabilities | 2.4m |
Other Current Liabilities | 76k |
Non-Current Liabilities | 248k |
Other Non-Current Liabilities | 248k |
Earnings Waterfall
Cortexyme Inc
Revenue
|
0
USD
|
Operating Expenses
|
-51.2m
USD
|
Operating Income
|
-51.2m
USD
|
Other Expenses
|
-470k
USD
|
Net Income
|
-51.7m
USD
|
Free Cash Flow Analysis
Cortexyme Inc
CRTX Profitability Score
Profitability Due Diligence
Cortexyme Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Cortexyme Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
CRTX Solvency Score
Solvency Due Diligence
Cortexyme Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Cortexyme Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRTX Price Targets Summary
Cortexyme Inc
Ownership
CRTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CRTX Price
Cortexyme Inc
Average Annual Return | 7.81% |
Standard Deviation of Annual Returns | 76.5% |
Max Drawdown | -99% |
Market Capitalization | 48.3m USD |
Shares Outstanding | 36 150 800 |
Percentage of Shares Shorted | 14.39% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The firm provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The firm's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The firm is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.
Contact
IPO
Employees
Officers
The intrinsic value of one CRTX stock under the Base Case scenario is 2.59 USD.
Compared to the current market price of 1.33 USD, Cortexyme Inc is Undervalued by 49%.